Publication Name	World Journal of Clinical Oncology
Manuscript ID	106107
Country	India

Received	2025-02-17 07:47
Peer-Review Started	2025-02-17 07:47
To Make the First Decision
Return for Revision	2025-04-03 08:57
Revised	2025-04-16 05:07
Second Decision	2025-06-03 02:55
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-06-03 09:49
Articles in Press	2025-06-03 09:49
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2025-07-09 09:05
Publish the Manuscript Online	2025-07-22 09:23

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Minireviews
Article Title	Optimizing neoadjuvant chemoradiation in resectable and borderline resectable pancreatic cancer: Evidence-based insights
Manuscript Source	Invited Manuscript
All Author List	Gautam Sarma, Hima Bora and Partha P Medhi
Funding Agency and Grant Number
Corresponding Author	Hima Bora, Researcher, Department of Radiation Oncology, Tezpur Medical College and Hospital, NH-15, Tezpur 784010, Assam, India. himabora36@gmail.com
Key Words	Pancreatic adenocarcinoma; Resectable pancreatic cancer; Borderline resectable pancreatic cancer; Neoadjuvant therapy; Adjuvant therapy
Core Tip	Recognized from its inception as a systemic disease, localized pancreatic cancer is currently treated with adjuvant chemotherapy and surgical excision to improve survival rates. However, the main obstacle that may postpone or prevent the prompt delivery of adjuvant therapy is the high morbidity and delayed recovery that follows large surgical excision. Thus, acknowledging the potential of neoadjuvant chemoradiation in improving long-term survival and the chance of successful resection for a variety of digestive tract cancers, such as rectal, gastric, and oesophagal cancers, researchers have focused on investigating its potential benefits in the context of both resectable and borderline resectable pancreatic cancer.
Publish Date	2025-07-22 09:23
Citation	<p>Sarma G, Bora H, Medhi PP. Optimizing neoadjuvant chemoradiation in resectable and borderline resectable pancreatic cancer: Evidence-based insights. <i>World J Clin Oncol</i> 2025; 16(7): 106107</p>
URL	https://www.wjgnet.com/2218-4333/full/v16/i7/106107.htm
DOI	https://dx.doi.org/10.5306/wjco.v16.i7.106107

Full Article (PDF)	WJCO-16-106107-with-cover.pdf
Manuscript File	106107_Auto_Edited_105839.docx
Answering Reviewers	106107-answering-reviewers.pdf
Audio Core Tip	106107-audio.mp3
Conflict-of-Interest Disclosure Form	106107-conflict-of-interest-statement.pdf
Copyright License Agreement	106107-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	106107-non-native-speakers.pdf
Peer-review Report	106107-peer-reviews.pdf
Scientific Misconduct Check	106107-scientific-misconduct-check.png
Scientific Editor Work List	106107-scientific-editor-work-list.pdf
CrossCheck Report	106107-crosscheck-report.pdf